anurajms/meta_analysis huggingface dataset:
MESH terms:
Telerehabilitation services for stroke
1. Activities of Daily Living; 2. Randomized Controlled Trials as Topic; 3. Stroke [psychology, *therapy]; 4. Stroke Rehabilitation [*methods]; 5. Telerehabilitation [*methods];
MESH terms:
Pharmacy‐based management for depression in adults
1. *Medication Adherence; 2. Antidepressive Agents [adverse effects, *therapeutic use]; 3. Depressive Disorder [*drug therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Manually‐generated reminders delivered on paper: effects on professional practice and patient outcomes
1. Clinical Competence; 2. Decision Support Systems, Clinical; 3. *Evidence-Based Medicine; 4. Health Personnel [*psychology]; 5. Outcome and Process Assessment, Health Care; 6. Patient Compliance; 7. Practice Patterns, Physicians' [standards]; 8. Professional Practice [*standards]; 9. Quality Improvement; 10. *Quality of Health Care; 11. Randomized Controlled Trials as Topic; 12. *Reminder Systems;
MESH terms:
Telephone counselling for smoking cessation
1. Counseling [*methods]; 2. Hotlines; 3. Randomized Controlled Trials as Topic; 4. Smoking Cessation [*methods, *statistics & numerical data]; 5. *Telephone;
MESH terms:
Follow‐up services for improving long‐term outcomes in intensive care unit (ICU) survivors
1. *Continuity of Patient Care; 2. *Needs Assessment; 3. *Quality of Life; 4. *Survivors; 5. Anxiety [prevention & control]; 6. Cognition; 7. Critical Care [*psychology]; 8. Depression [prevention & control]; 9. Intensive Care Units; 10. Non‐Randomized Controlled Trials as Topic; 11. Physical Functional Performance; 12. Practice Patterns, Nurses'; 13. Program Evaluation; 14. Randomized Controlled Trials as Topic; 15. Return to Work; 16. Stress Disorders, Post‐Traumatic [prevention & control]; 17. Treatment Outcome;
MESH terms:
Patient‐mediated interventions to improve professional practice
1. *Patient Education as Topic; 2. *Patient Reported Outcome Measures; 3. *Professional‐Patient Relations; 4. *Quality Improvement; 5. Decision Support Techniques; 6. Patient Participation [methods, statistics & numerical data]; 7. Patient Satisfaction [statistics & numerical data]; 8. Professional Practice [*standards]; 9. Quality of Health Care [*standards]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Impact of public release of performance data on the behaviour of healthcare consumers and providers
1. *Information Dissemination; 2. *Quality Improvement; 3. Canada; 4. Clinical Decision‐Making; 5. Consumer Health Information [*methods]; 6. Evaluation Studies as Topic; 7. Health Maintenance Organizations [standards]; 8. Health Services Needs and Demand [standards]; 9. Hospitals [*standards]; 10. Medicaid; 11. Organizational Innovation; 12. Quality Assurance, Health Care [*methods]; 13. Randomized Controlled Trials as Topic; 14. Reproducibility of Results; 15. Treatment Outcome; 16. United States;
MESH terms:
Pharmacist services for non‐hospitalised patients
1. *Treatment Outcome; 2. Ambulatory Care [methods, *statistics & numerical data]; 3. Community Pharmacy Services [statistics & numerical data]; 4. Delivery of Health Care [methods, *statistics & numerical data]; 5. Drug‐Related Side Effects and Adverse Reactions [therapy]; 6. Hospitalization [statistics & numerical data]; 7. Hypertension [therapy]; 8. Medication Therapy Management [statistics & numerical data]; 9. Mortality; 10. Outpatients; 11. Pharmaceutical Services [*statistics & numerical data]; 12. Pharmacy Service, Hospital [statistics & numerical data]; 13. Physical Fitness; 14. Randomized Controlled Trials as Topic;
MESH terms:
Hospitalisation in short‐stay units for adults with internal medicine diseases and conditions
1. *Internal Medicine; 2. *Length of Stay; 3. Activities of Daily Living; 4. Asthma; 5. Atrial Fibrillation; 6. Chest Pain; 7. Heart Failure; 8. Hospital Mortality; 9. Hospital Units [*classification]; 10. Ischemic Attack, Transient; 11. Patient Readmission; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Syncope; 15. Time Factors;
MESH terms:
Nurses as substitutes for doctors in primary care
1. *Practice Patterns, Nurses'; 2. Family Practice [economics, *organization & administration]; 3. Health Services Needs and Demand [economics, *organization & administration]; 4. Nurse Practitioners [organization & administration]; 5. Nursing Staff [*organization & administration]; 6. Personnel Delegation [*organization & administration]; 7. Primary Health Care [economics, *organization & administration]; 8. Quality of Health Care; 9. Randomized Controlled Trials as Topic;
MESH terms:
Improving adherence to Standard Precautions for the control of health care‐associated infections
1. *Universal Precautions; 2. Cross Infection [*prevention & control]; 3. Guideline Adherence [*standards]; 4. Health Knowledge, Attitudes, Practice; 5. Methicillin‐Resistant Staphylococcus aureus; 6. Non‐Randomized Controlled Trials as Topic; 7. Personnel, Hospital [*education]; 8. Randomized Controlled Trials as Topic; 9. Staphylococcal Infections [prevention & control];
MESH terms:
Comprehensive geriatric assessment for older people admitted to a surgical service
1. *Geriatric Assessment; 2. *Length of Stay; 3. Delirium [epidemiology]; 4. Elective Surgical Procedures [mortality]; 5. Hip Fractures [mortality, *surgery]; 6. Neoplasms [mortality, *surgery]; 7. Patient Readmission [statistics & numerical data]; 8. Postoperative Complications [epidemiology]; 9. Randomized Controlled Trials as Topic; 10. Treatment Outcome;
MESH terms:
Patient reminder and recall interventions to improve immunization rates
1. Correspondence as Topic; 2. Immunization [*statistics & numerical data]; 3. Immunization Programs [organization & administration]; 4. Randomized Controlled Trials as Topic; 5. *Reminder Systems [statistics & numerical data]; 6. Telephone [statistics & numerical data]; 7. Text Messaging [statistics & numerical data];
MESH terms:
Providing physicians with feedback on medication adherence for people with chronic diseases taking long‐term medication
1. *Feedback; 2. *Physician's Role; 3. Interrupted Time Series Analysis; 4. Medication Adherence [*statistics & numerical data]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity
1. Body Weight; 2. Controlled Clinical Trials as Topic; 3. Delivery of Health Care [organization & administration, standards]; 4. Obesity [psychology, *therapy]; 5. Overweight [psychology, therapy]; 6. Patient Education as Topic; 7. Professional Practice [organization & administration, *standards]; 8. Randomized Controlled Trials as Topic; 9. Weight Loss;
MESH terms:
Comprehensive geriatric assessment for older adults admitted to hospital
1. *Frail Elderly; 2. *Hospitalization; 3. *Outcome and Process Assessment, Health Care; 4. Comprehensive Health Care [*methods]; 5. Emergencies; 6. Geriatric Assessment [*methods]; 7. Independent Living [statistics & numerical data]; 8. Mortality;
MESH terms:
Interprofessional collaboration to improve professional practice and healthcare outcomes
1. *Cooperative Behavior; 2. *Health Personnel; 3. *Interprofessional Relations; 4. *Professional Practice; 5. Allied Health Occupations; 6. Checklist; 7. Delivery of Health Care; 8. Nurses; 9. Pharmacists; 10. Physicians; 11. Quality of Health Care; 12. Randomized Controlled Trials as Topic; 13. Social Workers; 14. Telecommunications;
MESH terms:
Home or foster home care versus institutional long‐term care for functionally dependent older people
1. *Community Health Services; 2. *Disabled Persons; 3. *Foster Home Care; 4. *Long‐Term Care; 5. Activities of Daily Living; 6. Happiness; 7. Mortality; 8. Non‐Randomized Controlled Trials as Topic; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
Non‐medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care
1. Acute Disease [*therapy]; 2. Blood Pressure; 3. Chronic Disease [*drug therapy]; 4. Developed Countries; 5. Developing Countries; 6. Diabetes Mellitus [drug therapy]; 7. Drug Prescriptions [*standards]; 8. Glycated Hemoglobin [analysis]; 9. Interrupted Time Series Analysis; 10. Lipoproteins, LDL [blood]; 11. Medication Adherence; 12. Patient Satisfaction; 13. *Pharmacists; 14. *Practice Patterns, Nurses'; 15. Professional Autonomy; 16. Quality of Life; 17. Randomized Controlled Trials as Topic;
MESH terms:
Tools developed and disseminated by guideline producers to promote the uptake of their guidelines
1. *Practice Guidelines as Topic; 2. Delivery of Health Care [economics, *standards]; 3. Family Practice; 4. Guideline Adherence [*statistics & numerical data]; 5. Health Resources [statistics & numerical data]; 6. Medical Staff, Hospital; 7. Physical Therapy Specialty [education]; 8. Randomized Controlled Trials as Topic; 9. Reminder Systems; 10. Teaching Materials;
MESH terms:
Mobile clinics for women's and children's health
1. *Health Education; 2. Asthma [*therapy]; 3. Child Health Services [economics, *statistics & numerical data]; 4. Cost‐Benefit Analysis; 5. Mammography [*statistics & numerical data]; 6. Maternal Health Services [economics, *statistics & numerical data]; 7. Mobile Health Units [economics, *statistics & numerical data]; 8. Randomized Controlled Trials as Topic; 9. United States;
MESH terms:
Integrated management of childhood illness (IMCI) strategy for children under five
1. *Disease Management; 2. Bangladesh; 3. Breast Feeding; 4. Child Health Services [*organization & administration]; 5. Child Mortality; 6. Controlled Before‐After Studies; 7. Delivery of Health Care, Integrated [*organization & administration]; 8. Developing Countries; 9. Health Personnel [education]; 10. House Calls; 11. India; 12. Infant Mortality; 13. Program Evaluation; 14. Quality Improvement; 15. Randomized Controlled Trials as Topic; 16. Tanzania;
MESH terms:
Professional interventions for general practitioners on the management of musculoskeletal conditions
1. *Bone Density; 2. Back Pain [diagnosis, therapy]; 3. Bone Density Conservation Agents [therapeutic use]; 4. Controlled Before‐After Studies; 5. General Practitioners [*education]; 6. Guideline Adherence; 7. Interrupted Time Series Analysis; 8. Musculoskeletal Diseases [*diagnosis, *therapy]; 9. Osteoarthritis [diagnosis, therapy]; 10. Osteoporosis [diagnosis, therapy]; 11. Randomized Controlled Trials as Topic; 12. Reminder Systems; 13. Shoulder Pain [diagnosis, therapy];
MESH terms:
Transition of care for adolescents from paediatric services to adult health services
1. *Adolescent Health Services; 2. Chronic Disease [*therapy]; 3. Diabetes Mellitus, Type 1 [blood, therapy]; 4. Heart Diseases [therapy]; 5. Practice Patterns, Nurses'; 6. Randomized Controlled Trials as Topic; 7. Self Care [standards]; 8. Spinal Dysraphism [therapy]; 9. Transition to Adult Care [*standards];
MESH terms:
Interventions to optimise prescribing for older people in care homes
1. *Homes for the Aged; 2. *Nursing Homes; 3. Drug Prescriptions [*standards]; 4. Inappropriate Prescribing [*prevention & control]; 5. Medication Reconciliation; 6. Quality Improvement [*standards]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interactive telemedicine: effects on professional practice and health care outcomes
1. *Communication; 2. *Outcome and Process Assessment, Health Care; 3. *Physician‐Patient Relations; 4. *Practice Patterns, Physicians'; 5. Diabetes Mellitus [therapy]; 6. Heart Failure [therapy]; 7. Mental Disorders [therapy]; 8. Monitoring, Physiologic [methods]; 9. Telemedicine [*methods]; 10. Videoconferencing;
MESH terms:
Alternative versus standard packages of antenatal care for low‐risk pregnancy
1. *Perinatal Mortality; 2. Developed Countries; 3. Developing Countries; 4. Family Practice; 5. Midwifery; 6. Office Visits [*statistics & numerical data]; 7. Patient Satisfaction; 8. Pregnancy Outcome; 9. Prenatal Care [*standards, statistics & numerical data]; 10. Program Evaluation; 11. Randomized Controlled Trials as Topic;
MESH terms:
Medical day hospital care for older people versus alternative forms of care
1. *Geriatrics; 2. Activities of Daily Living; 3. Day Care, Medical [*standards, statistics & numerical data]; 4. Health Services Research; 5. Health Services for the Aged [*statistics & numerical data]; 6. Home Care Services [standards]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Chronic disease management programmes for adults with asthma
1. *Disease Management; 2. Asthma [*therapy]; 3. Chronic Disease; 4. Hospitalization; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Self Care [methods];
MESH terms:
In‐service training for health professionals to improve care of seriously ill newborns and children in low‐income countries
1. *Developing Countries; 2. Inservice Training [*methods]; 3. Neonatology [*education]; 4. Perinatology [*education]; 5. Quality of Health Care [*standards]; 6. Randomized Controlled Trials as Topic; 7. Resuscitation [education];
MESH terms:
Case management approaches to home support for people with dementia
1. *Case Management [economics]; 2. Alzheimer Disease [nursing]; 3. Caregivers [psychology, statistics & numerical data]; 4. Dementia [*nursing]; 5. Depression [epidemiology]; 6. Health Care Costs; 7. Home Nursing [economics, *methods]; 8. Hospitalization [statistics & numerical data]; 9. Long‐Term Care [economics, methods]; 10. Randomized Controlled Trials as Topic; 11. Time Factors;
MESH terms:
Dental auxiliaries for dental care traditionally provided by dentists
1. *Dental Atraumatic Restorative Treatment; 2. *Dental Auxiliaries; 3. Dental Care [*standards]; 4. Dental Caries [*prevention & control]; 5. Dental Restoration Failure [statistics & numerical data]; 6. *Dentists; 7. Pit and Fissure Sealants [*therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Time Factors; 10. Treatment Outcome;
MESH terms:
Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy
1. Africa; 2. Anti‐HIV Agents [*therapeutic use]; 3. Cohort Studies; 4. Delegation, Professional [*standards]; 5. General Practice [standards]; 6. HIV Infections [*drug therapy, mortality]; 7. Health Services Accessibility [economics]; 8. Induction Chemotherapy [standards]; 9. Lost to Follow‐Up; 10. Maintenance Chemotherapy [standards]; 11. Practice Patterns, Nurses' [*standards]; 12. Practice Patterns, Physicians' [standards]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Computerized advice on drug dosage to improve prescribing practice
1. *Drug Therapy, Computer‐Assisted; 2. *Practice Patterns, Physicians'; 3. Dosage Forms; 4. Medication Errors [prevention & control]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Nutritional screening for improving professional practice for patient outcomes in hospital and primary care settings
1. Hospitals; 2. Malnutrition [*diagnosis]; 3. *Nutrition Assessment; 4. Primary Health Care; 5. *Professional Practice; 6. Program Evaluation; 7. *Quality Improvement;
MESH terms:
Managerial supervision to improve primary health care in low‐ and middle‐income countries
1. *Developing Countries; 2. Controlled Clinical Trials as Topic [methods]; 3. Health Personnel [*organization & administration]; 4. Personnel Management [methods, *standards]; 5. Primary Health Care [*standards]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Dressings and topical agents containing hyaluronic acid for chronic wound healing
1. Bandages; 2. *Diabetic Foot [therapy]; 3. *Hyaluronic Acid [therapeutic use]; 4. *Pressure Ulcer [therapy]; 5. Randomized Controlled Trials as Topic; 6. *Wound Healing;
MESH terms:
Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
1. Bevacizumab [therapeutic use]; 2. *Diabetes Mellitus [drug therapy]; 3. *Diabetic Retinopathy [complications, drug therapy]; 4. Endothelial Growth Factors [therapeutic use]; 5. Laser Coagulation [methods]; 6. *Macular Edema [drug therapy, etiology, surgery]; 7. Network Meta-Analysis; 8. Ranibizumab [therapeutic use]; 9. Vascular Endothelial Growth Factor A;
MESH terms:
Fenofibrate for diabetic retinopathy
1. *Diabetes Mellitus, Type 1; 2. *Diabetes Mellitus, Type 2 [complications, drug therapy]; 3. *Diabetic Retinopathy [drug therapy]; 4. *Fenofibrate [adverse effects]; 5. *Macular Edema [drug therapy, etiology]; 6. *Retinal Diseases;
MESH terms:
Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial disease or diabetes
1. Amputation, Surgical; 2. *Diabetes Mellitus; 3. *Peripheral Arterial Disease [surgery]; 4. *Phantom Limb; 5. Walking;
MESH terms:
Anti‐vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy
1. *Diabetes Mellitus; 2. *Diabetic Retinopathy [complications, surgery]; 3. Endothelial Growth Factors; 4. Postoperative Hemorrhage [surgery]; 5. *Retinal Detachment [etiology, surgery]; 6. *Retinal Perforations [complications]; 7. Silicone Oils; 8. Vitrectomy [adverse effects];
MESH terms:
Blood pressure control for diabetic retinopathy
1. Antihypertensive Agents [therapeutic use]; 2. Blood Pressure; 3. *Diabetes Mellitus, Type 2 [complications]; 4. *Diabetic Retinopathy [complications, epidemiology, prevention & control]; 5. *Hypertension [complications, drug therapy]; 6. *Macular Edema [etiology]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy
1. *Diabetes Mellitus [drug therapy]; 2. *Diabetic Retinopathy [complications, drug therapy]; 3. Ranibizumab [therapeutic use]; 4. Vascular Endothelial Growth Factor A [antagonists & inhibitors]; 5. Vitreous Hemorrhage [drug therapy, etiology, surgery];
MESH terms:
Parathyroidectomy for adults with primary hyperparathyroidism
1. *Cardiovascular Diseases; 2. *Hypercalcemia [etiology]; 3. *Hyperparathyroidism, Primary [complications, surgery]; 4. *Osteoporosis; 5. Parathyroid Hormone; 6. Parathyroidectomy [adverse effects]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes
1. *Diabetes Mellitus, Type 2 [prevention & control]; 2. *Diabetes, Gestational [prevention & control, therapy]; 3. Dietary Supplements; 4. *Hypertension, Pregnancy-Induced; 5. Inositol [therapeutic use]; 6. *Insulin Resistance; 7. Perinatal Death; 8. Premature Birth;
MESH terms:
Pharmacological interventions for prevention of weight gain in people with schizophrenia
1. *Antipsychotic Agents [adverse effects]; 2. Betahistine [therapeutic use]; 3. Famotidine [therapeutic use]; 4. Fluoxetine [therapeutic use]; 5. *Melatonin [therapeutic use]; 6. *Metformin [therapeutic use]; 7. Nausea [drug therapy]; 8. Nizatidine [therapeutic use]; 9. Ranitidine [therapeutic use]; 10. Reboxetine [therapeutic use]; 11. *Schizophrenia [drug therapy, prevention & control]; 12. Topiramate [therapeutic use]; 13. Weight Gain;
MESH terms:
Rituximab for thyroid‐associated ophthalmopathy
1. Antibodies, Monoclonal [therapeutic use]; 2. Diplopia [drug therapy]; 3. *Graves Ophthalmopathy [drug therapy]; 4. Mice; 5. Rituximab [adverse effects];
MESH terms:
Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre
1. *Goiter; 2. Iodine Radioisotopes [therapeutic use]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Thyrotropin; 6. *Thyrotropin Alfa;
MESH terms:
Through‐knee versus above‐knee amputation for vascular and non‐vascular major lower limb amputations
1. *Amputation, Surgical; 2. Lower Extremity [surgery]; 3. *Peripheral Vascular Diseases [surgery]; 4. Randomized Controlled Trials as Topic; 5. Systematic Reviews as Topic; 6. Walking;
MESH terms:
Continuous glucose monitoring systems for monitoring cystic fibrosis‐related diabetes
1. Blood Glucose; 2. Blood Glucose Self-Monitoring; 3. *Cystic Fibrosis [complications]; 4. *Diabetes Mellitus; 5. Retrospective Studies;
MESH terms:
Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis
1. Bayes Theorem; 2. Bias; 3. *Dietary Supplements [adverse effects]; 4. Network Meta-Analysis; 5. Non-alcoholic Fatty Liver Disease [complications, *therapy]; 6. Odds Ratio; 7. Proportional Hazards Models; 8. Randomized Controlled Trials as Topic;
MESH terms:
Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis
1. Bayes Theorem; 2. Bias; 3. Caloric Restriction; 4. Diet, Carbohydrate-Restricted; 5. Diet, Mediterranean; 6. Exercise; 7. Follow-Up Studies; 8. *Life Style; 9. Network Meta-Analysis; 10. Non-alcoholic Fatty Liver Disease [complications, *therapy]; 11. Odds Ratio; 12. Randomized Controlled Trials as Topic; 13. Resistance Training; 14. Time Factors;
MESH terms:
Interventions for weight loss in people with chronic kidney disease who are overweight or obese
1. Bias; 2. Blood Pressure; 3. Body Mass Index; 4. Cause of Death; 5. Cholesterol [blood]; 6. Confidence Intervals; 7. Energy Intake; 8. Kidney Failure, Chronic [blood, therapy]; 9. Obesity [blood, complications, therapy]; 10. Overweight [blood, complications, *therapy]; 11. Proteinuria [epidemiology]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Renal Insufficiency, Chronic [blood, complications, *therapy]; 15. Waist Circumference; 16. *Weight Loss;
MESH terms:
Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
1. Antidepressive Agents, Tricyclic [therapeutic use]; 2. Antioxidants [therapeutic use]; 3. Antipsychotic Agents [*therapeutic use]; 4. Blood Glucose [analysis]; 5. Body Mass Index; 6. *Developing Countries; 7. Diabetes Mellitus, Type 2 [complications, *prevention & control]; 8. Fasting [blood]; 9. Hypoglycemic Agents [therapeutic use]; 10. Melatonin [therapeutic use]; 11. Mental Disorders [complications]; 12. Metformin [therapeutic use]; 13. Patient Dropouts [statistics & numerical data]; 14. Placebos [therapeutic use]; 15. Randomized Controlled Trials as Topic; 16. Schizophrenia [complications, *drug therapy]; 17. Selective Serotonin Reuptake Inhibitors [therapeutic use];
MESH terms:
Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes
1. Amputation, Surgical; 2. Bandages; 3. *Diabetes Mellitus; 4. *Diabetic Foot [therapy]; 5. Psychosocial Intervention; 6. Wound Healing;
MESH terms:
Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women
1. Androgen Antagonists [*therapeutic use]; 2. Drug Therapy, Combination [methods]; 3. Estradiol [*therapeutic use]; 4. Estrogens [*therapeutic use]; 5. Placebos [therapeutic use]; 6. Sex Reassignment Procedures [*methods]; 7. *Transgender Persons;
MESH terms:
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
1. Acarbose [therapeutic use]; 2. Bias; 3. Carbamates [therapeutic use]; 4. Cardiovascular Diseases [mortality]; 5. Confidence Intervals; 6. Diabetes Mellitus, Type 2 [complications, *prevention & control]; 7. Hypoglycemic Agents [*therapeutic use]; 8. Metformin [therapeutic use]; 9. Pioglitazone [*therapeutic use]; 10. Piperidines [therapeutic use]; 11. Placebos [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Risk;
MESH terms:
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
1. Bias; 2. Diabetes Mellitus, Type 2 [blood, complications, *drug therapy]; 3. Hemoglobin A [metabolism]; 4. Hypoglycemia [chemically induced]; 5. Hypoglycemic Agents [adverse effects, *therapeutic use]; 6. Insulin Detemir [adverse effects, *therapeutic use]; 7. Insulin Glargine [adverse effects, *therapeutic use]; 8. Insulin, Isophane [adverse effects, *therapeutic use]; 9. Insulin, Long-Acting [adverse effects, *therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults
1. Bias; 2. Hyperparathyroidism, Primary [blood, *diagnostic imaging, *surgery]; 3. Hypocalcemia [epidemiology]; 4. Minimally Invasive Surgical Procedures [adverse effects, methods]; 5. Monitoring, Intraoperative [*methods]; 6. Neck [surgery]; 7. Neck Dissection [methods]; 8. Operative Time; 9. Parathyroid Hormone [*blood]; 10. Parathyroidectomy [adverse effects, *methods]; 11. Postoperative Complications [epidemiology]; 12. Quality of Life; 13. Vocal Cord Paralysis [epidemiology];
MESH terms:
Nutritional interventions for treating foot ulcers in people with diabetes
1. Arginine [administration & dosage]; 2. Diabetic Foot [*diet therapy]; 3. Dietary Proteins [administration & dosage]; 4. Dietary Supplements; 5. Fatty Acids, Omega-3 [administration & dosage]; 6. Glutamine [administration & dosage]; 7. Magnesium [administration & dosage]; 8. Magnesium Oxide [administration & dosage]; 9. Minerals [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Trace Elements [administration & dosage]; 12. Valerates [administration & dosage]; 13. Vitamins [administration & dosage]; 14. *Wound Healing; 15. Zinc Sulfate [administration & dosage];
MESH terms:
Metformin monotherapy for adults with type 2 diabetes mellitus
1. Carbamates [adverse effects, therapeutic use]; 2. Cardiovascular Diseases [mortality]; 3. Cause of Death; 4. Diabetes Mellitus, Type 2 [*drug therapy, mortality]; 5. Dipeptidyl-Peptidase IV Inhibitors [adverse effects, therapeutic use]; 6. Glucagon-Like Peptide 1 [analogs & derivatives]; 7. Hypoglycemic Agents [adverse effects, *therapeutic use]; 8. Insulin [therapeutic use]; 9. Metformin [adverse effects, *therapeutic use]; 10. Myocardial Infarction [epidemiology]; 11. Piperidines [adverse effects, therapeutic use]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Stroke [epidemiology]; 15. Sulfonylurea Compounds [adverse effects, therapeutic use];
MESH terms:
Non‐nutritive sweeteners for diabetes mellitus
1. Bias; 2. Body Weight; 3. Diabetes Mellitus, Type 1 [blood, complications, *diet therapy]; 4. Diabetes Mellitus, Type 2 [blood, complications, *diet therapy]; 5. Glycated Hemoglobin [analysis]; 6. Non-Nutritive Sweeteners [*administration & dosage, adverse effects]; 7. Nutritive Sweeteners [administration & dosage]; 8. Placebos [therapeutic use]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
Zinc supplementation for the promotion of growth and prevention of infections in infants less than six months of age
1. Body Weight; 2. *Growth; 3. Infant Mortality; 4. Infection Control [*methods]; 5. Randomized Controlled Trials as Topic; 6. Riboflavin [administration & dosage]; 7. Trace Elements [*administration & dosage]; 8. Vitamin B Complex [administration & dosage]; 9. Wasting Syndrome [prevention & control]; 10. Zinc [*administration & dosage, *deficiency];
MESH terms:
Resveratrol for adults with type 2 diabetes mellitus
1. Blood Glucose [drug effects, metabolism]; 2. Diabetes Mellitus, Type 2 [*drug therapy]; 3. Fasting [blood]; 4. Hypoglycemic Agents [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Resveratrol [*therapeutic use]; 7. Treatment Outcome;
MESH terms:
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
1. Diabetes Mellitus, Type 2 [*prevention & control]; 2. Glucose Intolerance; 3. Hypoglycemic Agents [*therapeutic use]; 4. Metformin [*therapeutic use]; 5. Prediabetic State; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome
1. Androgens [therapeutic use]; 2. Body Height [*drug effects]; 3. Human Growth Hormone [*therapeutic use]; 4. Oxandrolone [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Turner Syndrome [complications, *drug therapy];
MESH terms:
Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
1. Abortion, Spontaneous [epidemiology]; 2. Autoimmune Diseases [*drug therapy]; 3. Fertilization in Vitro; 4. *Hormone Replacement Therapy [adverse effects]; 5. Hypothyroidism [blood, *drug therapy]; 6. Infertility, Female [*drug therapy]; 7. Live Birth [epidemiology]; 8. Pregnancy, Multiple; 9. Randomized Controlled Trials as Topic; 10. Reproductive Techniques, Assisted; 11. Sperm Injections, Intracytoplasmic; 12. Thyroid Diseases [blood, *drug therapy]; 13. Thyroid Gland [immunology]; 14. Thyrotropin [blood]; 15. Thyroxine [adverse effects, blood, *therapeutic use];
MESH terms:
Techniques of monitoring blood glucose during pregnancy for women with pre‐existing diabetes
1. Blood Glucose [*metabolism]; 2. Blood Glucose Self-Monitoring [*methods]; 3. Canada; 4. Diabetes Mellitus, Type 1 [*blood]; 5. Diabetes Mellitus, Type 2 [*blood]; 6. Europe; 7. Hypertension [prevention & control]; 8. Hypoglycemia [chemically induced]; 9. Perinatal Mortality; 10. Pre-Eclampsia [prevention & control]; 11. United States;
MESH terms:
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
1. Diabetes Mellitus, Type 2 [*drug therapy]; 2. Drug Therapy, Combination; 3. Hypoglycemia [chemically induced]; 4. Hypoglycemic Agents [*therapeutic use]; 5. Metformin [*therapeutic use]; 6. Sulfonylurea Compounds [*therapeutic use]; 7. Treatment Outcome;
MESH terms:
Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults
1. Activities of Daily Living; 2. Adrenal Gland Neoplasms [*surgery]; 3. Adrenalectomy [adverse effects, *methods, mortality]; 4. Cause of Death; 5. Laparoscopy [adverse effects, *methods]; 6. Length of Stay; 7. Peritoneum; 8. Randomized Controlled Trials as Topic; 9. Retroperitoneal Space;
MESH terms:
Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
1. Acarbose [adverse effects, *therapeutic use]; 2. Blood Glucose [*drug effects]; 3. Cause of Death; 4. Diabetes Mellitus, Type 2 [epidemiology, *prevention & control]; 5. Diet; 6. Exercise; 7. Fasting [*blood]; 8. Glucose Intolerance [*drug therapy]; 9. Glycoside Hydrolase Inhibitors [adverse effects, *therapeutic use]; 10. Incidence; 11. Inositol [adverse effects, *analogs & derivatives, therapeutic use]; 12. Metformin [adverse effects, therapeutic use]; 13. Prediabetic State [drug therapy]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
1. *Inpatients; 2. Cause of Death; 3. Diabetes Mellitus, Type 2 [*drug therapy, mortality]; 4. Hypoglycemia [chemically induced]; 5. Hypoglycemic Agents [*administration & dosage, adverse effects]; 6. Insulin [*administration & dosage, adverse effects]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Tocilizumab for thyroid eye disease
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Graves Ophthalmopathy [*drug therapy, immunology]; 3. Interleukin‐6 [*antagonists & inhibitors];
MESH terms:
Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
1. *Amputation, Surgical; 2. *Bandages [statistics & numerical data]; 3. Debridement; 4. Diabetic Foot [*surgery]; 5. Negative-Pressure Wound Therapy [adverse effects, *methods, statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. *Wound Healing;
MESH terms:
Monotherapy laser photocoagulation for diabetic macular oedema
1. Diabetic Retinopathy [*complications]; 2. Laser Coagulation [*methods, statistics & numerical data]; 3. Lasers, Gas [therapeutic use]; 4. Macular Edema [etiology, *surgery]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. Visual Acuity;
MESH terms:
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes
1. Birth Weight; 2. Body Mass Index; 3. Hypertension [epidemiology]; 4. Hypoglycemic Agents [adverse effects, *therapeutic use]; 5. Metformin [adverse effects, *therapeutic use]; 6. *Obesity [complications]; 7. Overweight [complications]; 8. *Pregnancy Complications [epidemiology]; 9. Pregnancy Outcome; 10. Randomized Controlled Trials as Topic; 11. Weight Gain;
MESH terms:
Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema
1. Bevacizumab [*therapeutic use]; 2. Dexamethasone [*therapeutic use]; 3. Diabetic Retinopathy [*drug therapy, etiology, surgery]; 4. Drug Therapy, Combination [methods]; 5. Glucocorticoids [*therapeutic use]; 6. Intraocular Pressure; 7. Intravitreal Injections; 8. Macula Lutea [drug effects]; 9. Macular Edema [*drug therapy, etiology, surgery]; 10. Randomized Controlled Trials as Topic; 11. Ranibizumab [*therapeutic use]; 12. Receptors, Vascular Endothelial Growth Factor [antagonists & inhibitors]; 13. Triamcinolone [*therapeutic use]; 14. Vascular Endothelial Growth Factor A [*antagonists & inhibitors]; 15. Visual Acuity [drug effects];
MESH terms:
Different lasers and techniques for proliferative diabetic retinopathy
1. Diabetic Retinopathy [*surgery]; 2. Laser Therapy [*methods]; 3. Lasers, Solid‐State [*therapeutic use]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Planned birth at or near term for improving health outcomes for pregnant women with pre‐existing diabetes and their infants
1. *Cesarean Section; 2. *Diabetes Mellitus, Type 1; 3. *Diabetes Mellitus, Type 2; 4. *Labor, Induced; 5. *Pregnancy in Diabetics; 6. *Term Birth;
MESH terms:
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
1. *Diet; 2. *Exercise; 3. Cause of Death; 4. Combined Modality Therapy [methods]; 5. Diabetes Complications [prevention & control]; 6. Diabetes Mellitus, Type 2 [complications, epidemiology, *prevention & control]; 7. Diet, Diabetic; 8. Fasting [blood]; 9. Glucose Tolerance Test; 10. Incidence; 11. Randomized Controlled Trials as Topic; 12. Risk;
MESH terms:
Insulin for the treatment of women with gestational diabetes
1. Adiposity [drug effects]; 2. Body Weight; 3. Cesarean Section [statistics & numerical data]; 4. Diabetes Mellitus, Type 2 [etiology]; 5. Diabetes, Gestational [*drug therapy]; 6. Fetal Macrosomia [epidemiology]; 7. Hypoglycemia [chemically induced]; 8. Hypoglycemic Agents [adverse effects, *therapeutic use]; 9. Insulin [adverse effects, *therapeutic use]; 10. Labor, Induced [statistics & numerical data]; 11. Pre-Eclampsia [prevention & control]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Oral anti‐diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre‐existing diabetes
1. Administration, Oral; 2. Diabetes Mellitus [*drug therapy]; 3. Diabetes, Gestational [drug therapy]; 4. Glucose Intolerance [*drug therapy]; 5. Hypoglycemia [chemically induced]; 6. Hypoglycemic Agents [*administration & dosage]; 7. Insulin [therapeutic use]; 8. Metformin [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Psychological interventions for diabetes‐related distress in adults with type 2 diabetes mellitus
1. Depression [*therapy]; 2. Diabetes Mellitus, Type 2 [blood, *psychology]; 3. Glycated Hemoglobin [metabolism]; 4. *Psychotherapy; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Self Care [psychology]; 8. Stress, Psychological [*therapy];
MESH terms:
Preconception care for diabetic women for improving maternal and infant health
1. *CD-ROM; 2. Diabetes Mellitus, Type 1 [blood, *therapy]; 3. Diabetes Mellitus, Type 2 [blood, *therapy]; 4. Glycated Hemoglobin [metabolism]; 5. Intention to Treat Analysis; 6. Patient Education as Topic [methods]; 7. Preconception Care [*methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Phototherapy for treating foot ulcers in people with diabetes
1. Diabetic Foot [*therapy]; 2. Foot Ulcer [therapy]; 3. Phototherapy [adverse effects, *methods]; 4. Randomized Controlled Trials as Topic; 5. Wound Healing;
MESH terms:
Topical antimicrobial agents for treating foot ulcers in people with diabetes
1. Administration, Topical; 2. Anti‐Bacterial Agents [*administration & dosage, adverse effects]; 3. Bacterial Infections [complications, *drug therapy, epidemiology]; 4. Bandages, Hydrocolloid; 5. Diabetic Foot [complications, *drug therapy]; 6. Foot Ulcer [drug therapy]; 7. Incidence; 8. Intercellular Signaling Peptides and Proteins [administration & dosage]; 9. Randomized Controlled Trials as Topic [statistics & numerical data]; 10. Wound Healing [drug effects];
MESH terms:
Glucose targets for preventing diabetic kidney disease and its progression
1. Albuminuria [epidemiology]; 2. *Blood Glucose; 3. Cardiovascular Diseases [mortality, prevention & control]; 4. Cause of Death; 5. Creatinine [blood]; 6. Death, Sudden [epidemiology]; 7. Diabetes Mellitus, Type 1 [complications]; 8. Diabetes Mellitus, Type 2 [complications]; 9. Diabetic Nephropathies [blood, *prevention & control]; 10. Disease Progression; 11. Fasting [*blood]; 12. *Glycated Hemoglobin [analysis]; 13. Hyperglycemia [blood, drug therapy]; 14. Hypoglycemic Agents [therapeutic use]; 15. Kidney Failure, Chronic [blood, etiology, *prevention & control]; 16. Myocardial Infarction [mortality, prevention & control]; 17. Randomized Controlled Trials as Topic; 18. Stroke [epidemiology, prevention & control]; 19. Time Factors;
MESH terms:
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
1. Adamantane [analogs & derivatives, therapeutic use]; 2. Blood Glucose [metabolism]; 3. Diabetes Mellitus, Type 2 [complications, *prevention & control]; 4. Dipeptidyl-Peptidase IV Inhibitors [*therapeutic use]; 5. Exenatide; 6. Fasting; 7. Glucagon-Like Peptide 1 [*analogs & derivatives]; 8. Glucose Intolerance; 9. Glycated Hemoglobin [metabolism]; 10. Hypoglycemic Agents [therapeutic use]; 11. Incretins [*therapeutic use]; 12. Liraglutide [therapeutic use]; 13. Metformin [therapeutic use]; 14. Nitriles [therapeutic use]; 15. Peptides [therapeutic use]; 16. Pyrrolidines [therapeutic use]; 17. Randomized Controlled Trials as Topic; 18. Risk Factors; 19. Venoms [therapeutic use]; 20. Vildagliptin;
MESH terms:
Lifestyle interventions for the treatment of women with gestational diabetes
1. *Life Style; 2. Blood Glucose Self‐Monitoring; 3. Body Mass Index; 4. Body Weight; 5. Cesarean Section [statistics & numerical data]; 6. Depression, Postpartum [epidemiology]; 7. Diabetes Mellitus, Type 2 [etiology]; 8. Diabetes, Gestational [*therapy]; 9. Diet, Diabetic; 10. Exercise; 11. Infant, Postmature; 12. Labor, Induced [statistics & numerical data]; 13. Patient Education as Topic; 14. Perineum [injuries]; 15. Pre‐Eclampsia [epidemiology]; 16. Randomized Controlled Trials as Topic;
MESH terms:
Supportive interventions for enhancing dietary intake in malnourished or nutritionally at‐risk adults
1. Cause of Death; 2. Dietary Proteins [administration & dosage]; 3. *Dietary Supplements [adverse effects]; 4. Energy Intake; 5. Environment; 6. Hospitalization [statistics & numerical data]; 7. Malnutrition [*diet therapy, mortality]; 8. *Meals; 9. Nutritional Status; 10. Quality of Life; 11. Randomized Controlled Trials as Topic;
MESH terms:
Drug interventions for the treatment of obesity in children and adolescents
1. Anti‐Obesity Agents [adverse effects, *therapeutic use]; 2. Body Mass Index; 3. Cyclobutanes [therapeutic use]; 4. Fluoxetine [therapeutic use]; 5. Lactones [therapeutic use]; 6. Metformin [therapeutic use]; 7. Orlistat; 8. Pediatric Obesity [*drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
1. Benzamides [therapeutic use]; 2. Blood Glucose [analysis]; 3. Cardiovascular Diseases [mortality]; 4. Cyclohexanes [adverse effects, therapeutic use]; 5. Diabetes Mellitus, Type 2 [blood, mortality, *prevention & control]; 6. Fasting [blood]; 7. Hypoglycemic Agents [adverse effects, *therapeutic use]; 8. Insulin [*metabolism]; 9. Insulin Secretion; 10. Metformin [therapeutic use]; 11. Nateglinide; 12. Phenylalanine [adverse effects, analogs & derivatives, therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Sulfonylurea Compounds [adverse effects, *therapeutic use];
MESH terms:
Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
1. Diabetes Mellitus, Type 1 [blood, *drug therapy]; 2. Hypoglycemia [chemically induced]; 3. Hypoglycemic Agents [adverse effects, *therapeutic use]; 4. Insulin [adverse effects, *therapeutic use]; 5. Insulin Aspart [*therapeutic use]; 6. Insulin Lispro [*therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Fortification of staple foods with zinc for improving zinc status and other health outcomes in the general population
1. Anemia [therapy]; 2. Edible Grain; 3. *Food, Fortified; 4. Milk; 5. Randomized Controlled Trials as Topic; 6. Zinc [*administration & dosage, blood, *deficiency];
MESH terms:
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes
1. *Insulin Infusion Systems; 2. *Pregnancy in Diabetics; 3. Birth Weight; 4. Diabetes Mellitus, Type 1 [*drug therapy]; 5. Hypoglycemic Agents [*administration & dosage]; 6. Injections, Subcutaneous; 7. Insulin [*administration & dosage]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Autologous platelet‐rich plasma for treating chronic wounds
1. *Platelet‐Rich Plasma; 2. *Wound Healing; 3. Blood Transfusion, Autologous [methods]; 4. Chronic Disease; 5. Diabetic Foot [*therapy]; 6. Platelet Transfusion [*methods]; 7. Randomized Controlled Trials as Topic; 8. Varicose Ulcer [*therapy];
MESH terms:
Different intensities of glycaemic control for pregnant women with pre‐existing diabetes
1. Blood Glucose [*metabolism]; 2. Diabetes Mellitus, Type 1 [blood, *therapy]; 3. Diabetes Mellitus, Type 2 [blood]; 4. Fasting [blood]; 5. Glycated Hemoglobin [metabolism]; 6. Hyperglycemia [blood, therapy]; 7. Hypoglycemic Agents [therapeutic use]; 8. Insulin [therapeutic use]; 9. Pregnancy in Diabetics [blood, *therapy]; 10. Randomized Controlled Trials as Topic; 11. Reference Values;
MESH terms:
Self management interventions for type 2 diabetes in adult people with severe mental illness
1. Diabetes Mellitus, Type 2 [psychology, *therapy]; 2. Mental Disorders [*complications]; 3. Randomized Controlled Trials as Topic; 4. Self Care [*methods];
MESH terms:
Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
1. Benzhydryl Compounds [therapeutic use]; 2. Diabetes Mellitus, Type 2 [complications, *prevention & control]; 3. Fasting [blood]; 4. Glucose Intolerance [blood, complications]; 5. Glucosides [therapeutic use]; 6. Glycated Hemoglobin; 7. Hypoglycemic Agents [therapeutic use]; 8. Metformin [therapeutic use]; 9. Risk Factors; 10. *Sodium-Glucose Transporter 2 Inhibitors;
MESH terms:
Radioiodine therapy versus antithyroid medications for Graves' disease
1. Antithyroid Agents [*therapeutic use]; 2. Graves Disease [*therapy]; 3. Graves Ophthalmopathy [etiology]; 4. Iodine Radioisotopes [adverse effects, *therapeutic use]; 5. Methimazole [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Recurrence;
MESH terms:
Skin grafting and tissue replacement for treating foot ulcers in people with diabetes
1. *Wound Healing; 2. Amputation, Surgical [statistics & numerical data]; 3. Diabetic Foot [*surgery]; 4. Foot Ulcer [surgery]; 5. Randomized Controlled Trials as Topic; 6. Skin Transplantation [adverse effects, *methods];
MESH terms:
Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis
1. Diabetic Ketoacidosis [*drug therapy]; 2. Hypoglycemic Agents [adverse effects, *therapeutic use]; 3. Injections, Subcutaneous; 4. Insulin [therapeutic use]; 5. Insulin Aspart [therapeutic use]; 6. Insulin Lispro [therapeutic use]; 7. Insulin, Short‐Acting [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Intensive versus conventional glycaemic control for treating diabetic foot ulcers
1. Diabetes Mellitus, Type 1 [*complications]; 2. Diabetes Mellitus, Type 2 [*complications]; 3. Diabetic Foot [etiology, *therapy]; 4. Hyperglycemia [complications, *therapy];
MESH terms:
Parent‐only interventions for childhood overweight or obesity in children aged 5 to 11 years
1. Body Mass Index; 2. Body Weight; 3. Health Status; 4. Overweight [therapy]; 5. Parents [*education]; 6. Pediatric Obesity [*therapy]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Self Concept;
MESH terms:
Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy
1. Graves Disease [*surgery]; 2. Graves Ophthalmopathy [surgery]; 3. Randomized Controlled Trials as Topic; 4. Recurrence; 5. Remission Induction [methods]; 6. Reoperation; 7. Secondary Prevention; 8. Thyroidectomy [adverse effects, *methods];
MESH terms:
Growth factors for treating diabetic foot ulcers
1. Amputation, Surgical; 2. Diabetes Mellitus, Type 1 [*complications]; 3. Diabetes Mellitus, Type 2 [*complications]; 4. Diabetic Foot [*therapy]; 5. Growth Substances [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Wound Healing;
MESH terms:
Aromatase inhibitors for short stature in male children and adolescents
1. Aromatase Inhibitors [adverse effects, *therapeutic use]; 2. Body Height [*drug effects]; 3. Estrogens [metabolism]; 4. Growth Disorders [*drug therapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Testosterone [metabolism];
MESH terms:
Systemic antibiotics for treating diabetic foot infections
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Bacterial Infections [*drug therapy]; 3. Carbapenems [therapeutic use]; 4. Cephalosporins [therapeutic use]; 5. Diabetic Foot [*drug therapy]; 6. Fluoroquinolones [therapeutic use]; 7. Penicillins [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Complex interventions for preventing diabetic foot ulceration
1. Amputation, Surgical [*statistics & numerical data]; 2. Diabetic Foot [*prevention & control, surgery]; 3. Patient Education as Topic; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Total or near‐total thyroidectomy versus subtotal thyroidectomy for multinodular non‐toxic goitre in adults
1. Goiter, Nodular [*surgery]; 2. Randomized Controlled Trials as Topic; 3. Recurrence; 4. Reoperation [statistics & numerical data]; 5. Thyroid Neoplasms [epidemiology]; 6. Thyroidectomy [adverse effects, *methods]; 7. Vocal Cord Paralysis [epidemiology];
MESH terms:
Hyperbaric oxygen therapy for chronic wounds
1. *Wound Healing; 2. Chronic Disease; 3. Diabetic Foot [*therapy]; 4. Hyperbaric Oxygenation [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. Varicose Ulcer [*therapy];
MESH terms:
Topical non‐steroidal anti‐inflammatory agents for diabetic cystoid macular oedema
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Diabetic Retinopathy [complications, *drug therapy]; 3. Macular Edema [*drug therapy, etiology];
MESH terms:
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
1. Calcimimetic Agents [adverse effects, *therapeutic use]; 2. Calcium [blood]; 3. Cardiovascular Diseases [mortality]; 4. Cause of Death; 5. Cinacalcet; 6. Hyperparathyroidism, Secondary [blood, *drug therapy, etiology]; 7. Kidney Failure, Chronic [*complications, therapy]; 8. Naphthalenes [adverse effects, *therapeutic use]; 9. Parathyroid Hormone [blood]; 10. Phosphorus [blood]; 11. Randomized Controlled Trials as Topic; 12. Renal Dialysis;